The effect of co-administration of Dietary Approaches To Stop Hypertension (DASH) and Intermittent Fasting IF diets on patients with Non-Alcoholic Fatty Liver Disease (NAFLD): a Randomized Control Trial

Phase 2

Recruiting

• Conditions: on-alcoholic fatty liver.; Fatty (change of) liver, not elsewhere classified; K76.0

• Registration Number: IRCT20100524004010N39
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 25 July 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Age over 18 years
Having evidence of non-alcoholic fatty liver in fibroscan (CAP score>260)
Not having a history of alcohol consumption or alcohol consumption less than 10 grams per day in women and less than 20 grams per day in men.
Not taking drugs that affect blood lipids, metformin, vitamin E and ursodeoxycholic acid (UDCA) and hepatotoxic drugs such as phenytoin, amoxifen and lithium.
Not having chronic and acute liver diseases (hepatitis B, C, etc.), biliary disease, known autoimmune diseases, cancer and hereditary disorders affecting the liver (iron, copper storage disease)
No history of weight loss surgery, weight loss program in the last 3 months
Non-adherence to special diets such as vegetarianism
No history of uncontrolled thyroid disease
Willingness to participate in the studuy
Not having uncontrolled celiac disease, diabetes, cardiovascular disease, lung disease and kidney disease

Exclusion Criteria

History of weight loss surgery and weight loss program during the last 3 months
Failure to accept study conditions
Taking medicine or supplements that can affect the results
Following special diets and vegetarianism during the last 3 months
Pregnancy or breastfeeding in women or Using birth control pills

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evel of steatosis and liver fibrosis. Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Fibroscan.